Rapidly expanding exophthalmos: an unusual presentation of small cell lung cancer

RICHARD F SPAIDE,1 ELDER GRANGER,2 BRADLEY D HAMMER,1 FREDIE J NEGRON,3 AND PATRICK G PAGLEN4

From the 1Ophthalmology Service, the 2Oncology Service, and the 3Pulmonary Service of Landstuhl Army Regional Medical Center, and the 4Ophthalmology Service of the Wiesbaden Air Force Regional Medical Center, Federal Republic of Germany

SUMMARY A 61-year-old male presented with a rapidly progressive exophthalmos from small cell lung cancer metastatic to the right orbit. His vision in that eye was 20/200, and his intraocular pressure was 36 mmHg. The orbital metastasis responded dramatically to chemotherapy. One week after starting the chemotherapy the patient did not have exophthalmos, his vision was 20/20, and three weeks later the intraocular pressure was 12 mmHg.

Small cell lung cancer (SCLC) is one of the most aggressively metastatic tumours.1 It is the fifth leading cause of cancer death in the US, and only 1 to 2% of patients with disseminated disease at diagnosis achieve lasting remissions.1 This report describes a patient who presented with a rapidly progressing exophthalmos from an SCLC and his good response to chemotherapy.

Case report

A 61-year-old white male developed acute swelling of his right eyelids, and a diagnosis of preseptal cellulitis was made. The patient did not respond to antibiotics, so he was referred for further examination and treatment. On presentation he had a fullness of the right eyelids and temporal fossa. The globe was proptosed by about 10 mm and embedded in an indurated tumour mass that raised the conjunctiva. The preauricular node was enlarged on the right. The visual acuity was 20/200 in the right eye, 20/30 in the left eye, and there was a 2+ afferent pupillary defect in the right. The intraocular pressure was 36 mmHg in the right eye and 12 in the left.

Computed tomography of the orbit (Fig. 1) revealed a large homogeneous tumour in the right temporal fossa that continued round the edge of the right orbital margin into the orbit to the superior orbital fissure. The tumour extended round the medial part of the eye and encompassed the lacrimal sac. The posterior part of the globe was distorted, apparently because it was tethered by the stretched optic nerve. Chest roentgenography (Fig. 2) showed a widened mediastinum with asymmetrical bilateral hilar adenopathy.

A biopsy of the right lateral edge of the orbit revealed metastatic SCLC. We had planned to administer radiation therapy to the orbit for palliation, but our hospital does not have radiotherapy...
capabilities, and scheduling problems would have delayed treatment for one week. In the interim we administered induction chemotherapy directed against small cell lung cancer: Cytoxan (cyclophosphamide) 1000 mg/m² on day 1, Adriamycin (doxorubicin) 45 mg/m² intravenously on day 1, VP 16 (etopside) 80 mg/m² intravenously on days 1, 2, and 3. The orbital tumour had a good response to the chemotherapy. At one week after starting therapy he had minimal thickening of the lateral orbital rim and a faint subconjunctival infiltration. He had no proptosis; he was orthophoric in all fields of gaze, and his visual acuity was 20/20. The primary tumour in the lung completely resolved after three cycles of chemotherapy. The computed tomograph of his orbit showed a resolution of the tumour mass (Fig. 3). The intraocular pressure was 12 mmHg three weeks after treatment started.

Discussion

We wanted to treat this patient with radiation, but this proved unnecessary. Since patients with SCLC have to be treated with chemotherapy anyway, it might be better to start the chemotherapy immediately and use radiation therapy only if chemotherapy proves unsuccessful. Indeed, at one time superior vena caval obstruction in small cell lung cancer was considered a medical emergency requiring immediate radiotherapy, but now induction chemotherapy is the treatment of choice.3 We know of no other case of an orbital metastasis from SCLC treated with chemotherapy, but a previous report described a patient with SCLC metastatic to the iris who also had a striking response to chemotherapy.4

References


Accepted for publication 3 October 1988.